Non-infectious Intermediate, Posterior and Panuveitis flared in eye; covid; This spontaneous case was reported by a consumer and describes the occurrence of UVEITIS (Non-infectious Intermediate, Posterior and Panuveitis flared in eye) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 4782590) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect products included non-company products ADALIMUMAB (HUMIRA) for Uveitis and COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 vaccination.    Concurrent medical conditions included Uveitis.   On 12-Mar-2021, the patient received first dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (Intramuscular) 1 dosage form. On 11-Dec-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In May 2022, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram. On 01-Jul-2022, the patient experienced COVID-19 (covid). On 12-Oct-2022, the patient experienced UVEITIS (Non-infectious Intermediate, Posterior and Panuveitis flared in eye) (seriousness criterion medically significant). At the time of the report, UVEITIS (Non-infectious Intermediate, Posterior and Panuveitis flared in eye) was resolving and COVID-19 (covid) outcome was unknown. Not Provided          No Concomitant medications were provided. The patient experienced lack of effect of HUMIRA with Adalimumab Solution for Injection, Single Dose Pen in 2022 with outcome reported as unknown. The reporters causality for the event(s) of Non-infectious Intermediate, Posterior and Panuveitis flared in eye, covid and lack of effect of HUMIRA with Adalimumab Solution for Injection was Not Provided. The reporters causality for the event(s) of Non-infectious Intermediate, Posterior and Panuveitis flared in eye, covid and lack of effect of HUMIRA with Janssen COVID-19 vaccine (COVID-19 vaccine NRVV Ad26 (JNJ 78436735)) was Not Provided. It was unknown if patient was enrolled in COVID-19-Vaccine Trial. No treatment medications were provided.  Company Comment: This spontaneous case reported by a consumer, concerns a 40-year-old female patient, with concomitant use of adalimumab for Uveitis, who experienced the unexpected, serious (medically significant) event of uveitis(reported as Non-infectious Intermediate, Posterior and Panuveitis flared in eye), which occurred approximately 7 months after a dose of mRNA-1273 vaccine. Patient previously received 1 dose of Janssen COVID vaccine also experienced Non-serious event of Covid approximately 10 months after the mRNA-1273 vaccine. Uveitis is a progressive disease and in this case is confounded by lack of effect of adalimumab. Treatment details are not provided. The benefit-risk relationship of mRNA-1273 vaccine, is not affected by this report.   Reporter did not allow further contact; Sender's Comments: This spontaneous case reported by a consumer, concerns a 40-year-old female patient, with concomitant use of adalimumab for Uveitis, who experienced the unexpected, serious (medically significant) event of uveitis(reported as Non-infectious Intermediate, Posterior and Panuveitis flared in eye), which occurred approximately 7 months after a dose of mRNA-1273 vaccine. Patient previously received 1 dose of Janssen COVID vaccine also experienced Non-serious event of Covid approximately 10 months after the mRNA-1273 vaccine. Uveitis is a progressive disease and in this case is confounded by lack of effect of adalimumab. Treatment details are not provided. The benefit-risk relationship of mRNA-1273 vaccine, is not affected by this report.